Introduction {#Sec1}
============

Cancer cells must evade immune surveillance. Many molecular mechanisms present within both the cancer milieu and the cancer microenvironment participate in this process of evasion. RCAS1 is a well-known membrane protein that was discovered in 1996 by Sonoda ([@CR24]). More specifically, it is a membrane II protein that is expressed on various types of cancer cells, including those of ovarian cancer. The presence of RCAS1 expression correlates with a poor prognosis (Akahira et al. [@CR2]; Sonoda et al. [@CR29]; Enjoji et al. [@CR12]) for the case. This is because this protein is able to suppress cytotoxic T lymphocytes (CTLs) and NK cells (Nakashima et al. [@CR23]; Yoshida et al. [@CR33]) and it may evoke apoptosis of these mononuclear immune cells as well as trough activation of FADD in its cytoplasm (Matsushima et al. [@CR20]). Some recent research papers have revealed that RCAS1 expression is not limited to the cancer milieu but can also be detected within cells derived from the cancer microenvironment, such as macrophages or stromal cells (Adamek et al. [@CR1]; Dutsch-Wicherek [@CR5]; Dutsch-Wicherek et al. [@CR7]; Enjoji et al. [@CR13]). Moreover, the presence of RCAS1 within the cancer microenvironment seems to be related to the escape of the cancer cells from immune surveillance (Sonoda et al. [@CR24]; [@CR25]; [@CR26]; Giaginis et al. [@CR14]; Enjoji et al. [@CR10]). In a similar way, the function of RCAS1 is related to the soluble form of RCAS1 (Sonoda et al. [@CR24]; Giaginis et al. [@CR14]; Enjoji et al. [@CR10]; [@CR11]; Dutsch-Wicherek and Wicherek [@CR6]; Sonoda et al. [@CR31]). The soluble form of RCAS1, or sRCAS1, has been detected in the blood sera of patients with various types of carcinomas and, moreover, the level of sRCAS1 correlated inversely with the response to applied anti-cancer therapy (Dutsch-Wicherek and Wicherek [@CR6]; Sonoda et al. [@CR27]). It is well known that the status of the tumor microenvironment is crucial for the development of the cancer nest. Both stromal cells and even immune cells present within the tumor microenvironment may help the cancer to progress. The macrophages from the tumor microenvironment, called tumor-associated macrophages (TAM), may suppress the activity of cytotoxic immune cells. Most likely, this process is realized by the expression of various proteins present on the cell membrane of the macrophages, including B7H4 and RCAS1 (Adamek et al. [@CR1]; Dutsch-Wicherek [@CR5]; Dutsch-Wicherek et al. [@CR7]; Kryczek et al. [@CR19]; Kryczek et al. [@CR18]). As immune cells are able to suppress the activity of CTLs and NK cells, RCAS1-positive macrophages probably participate in generating the suppressive profile of the tumor microenvironment (Yoshida et al. [@CR33]). The cellular profile of the tumor microenvironment is important for the clinical outcome of the cancer patient treatment. Not only do the macrophages surrounding the tumor affect its homeostasis but recently carcinoma-associated fibroblasts (CAFs) have been identified as a cellular population important for tumor growth. Furthermore, tumor growth does not proceed uniformly (Wu et al. [@CR32]; Dutsch-Wicherek et al. [@CR8]; Dutsch-Wicherek et al. [@CR9]). Consequently, in advanced carcinoma it is possible to distinguish different zones within the tumor. For instance, one part of the tumor may be typified by strongly matched proliferation while another zone may be typified by apoptosis, necrosis, or hyalinization of the stroma. The development of metastases is linked with changes not only within the same tumor (e.g., the grading of cancer cells) but also in the cancer microenvironment itself. Most likely, the zones of the microenvironment associated with strong tumor growth (highly matched proliferation) differ from those zones in which there is highly marked hyalinization of the stroma. For this reason we decided to focus on RCAS1 immunoreactivity levels in the different parts of the tumor as well as in the different parts of its microenvironment. Since RCAS1 has been identified as a protein involved in the regulation of cytotoxic immune cells within the tumor microenvironment in patients with ovarian and cervical cancer, we selected RCAS1 for a planned immunohistochemical analysis that would examine the different zones in both the cancer milieu and in the cancer microenvironment.

In his study, Sonoda demonstrated that, while on the one hand, the intensity of the RCAS1 immunoreactivity in ovarian cancer cells was related to a poor prognosis for the case (Sonoda et al. [@CR30]), on the other hand, the presence of RCAS1 expression within the cervical cancer microenvironment was associated with the potential to develop metastases (Sonoda et al. [@CR25]; [@CR28]). The participation of RCAS1 in the development of metastases was also found in other types of adenocarcinoma (Dutsch-Wicherek et al. [@CR7]; Iwasaki et al. [@CR16]; Nakabayashi et al. [@CR22]). Recently, RCAS1 has been proposed as a clinically useful marker for detecting various kinds of adenocarcinoma (Ali-Fehmi et al. [@CR3]; Giaginis et al. [@CR15]). We therefore decided to analyze the RCAS1 immunoreactivity levels precisely, measuring them in a large group of patients treated for ovarian cancer with both surgery and subsequent chemotherapy. We detected the same kind of RCAS1 immunoreactivity profile within both the cancer milieu and the cancer microenvironment. The differences in RCAS1 immunoreactivity were analyzed according to different clinical parameters, including the kind of surgery performed and the response to the chemotherapy applied.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The patients included in the study were treated surgically for ovarian cancer between December 2006 and January 2010 in the Department of Gynecology and Oncology of the Lukaszczyk Oncological Center, Bydgoszcz, Poland. All of the 74 patients involved underwent optimal cytoreductive surgery either during the primary surgical procedure or following neoadjuvant chemotherapy. The histological characteristics of the tumors are able presented in Table [1](#Tab1){ref-type="table"}: grading, histological type and FIGO stage (Table [1](#Tab1){ref-type="table"}). The patients were divided according to the therapeutic strategy applied: These data are also presented in Table [1](#Tab1){ref-type="table"} (Table [1](#Tab1){ref-type="table"}). The patients included in our study were observed after the surgical procedure and chemotherapy in the Out-patient Unit of the Lukaszczyk Oncological Center, Bydgoszcz, Poland. The period of the follow up observation was from 1 to 5 years.Table 1Clinical characteristics of the patient and RCAS1 immunoreactivity changes correlating with different parts of the tumor and various clinico-pathological features (a precise description of these relationships was presented in the results section of chapters 2 and 3)DataN (%)Significant RCAS1 immunoreactivity correlating with different clinicopathological featuresAge54 (8)NoGradingYesG11 (1.3%)G225 (33.8%)G348 (64.9%)FIGOYesI20 (27.0%)II10 (13.5%)III44 (59.5%)IV0Ca125 before surgery1823.36NoSurgeryYesprimary cytoreductive surgery - optimally debulked55 (74.3%)neoadjuvant chemotherapy - secondary cytoreductive surgery19 (25.7%)AscitesYes042 (57.3%)132 (42.7%)HistologyNoSerous adenocarcinoma (ACS)31 (41.9%)Mucinous adenocarcinoma ( ACM)14 (18.9%)Endometrioid adenocarcinoma (ACE)7 (9.4%)Male differentiated (MD)10 (13.5%)Clear cell carcinoma (ACC)4 (5.4%)Granulosa cell tumors (GCTs)8 (10.9%)Number of chemotherapy regimensYes159 (79.7%)More than 115 (20.3%)

The patient's consent was obtained in each case. Prior to the present study we also obtained the approval of the Jagiellonian University Ethical Committee for our research program (DK/KB/CM/0031/447/2010).

Immunohistochemistry {#Sec4}
--------------------

The RCAS1 immunoreactivity levels were evaluated in samples obtained from 74 patients with primary ovarian cancer treated at the Lukaszczyk Oncology Center, Bydgoszcz, Poland. Formalin-fixed paraffin embedded 4 μm sections were de-waxed, hydrated gradually and incubated with an anti-RCAS1 antibody (ready to use; Medical & Biological Laboratories Co, Ltd, Japan) overnight at 4°C. The sections were then rinsed and incubated for 30 minutes with the EnVision peroxidase labeled polymer conjugated to anti-mouse secondary antibody (Dako, Carpinteria, CA). After washing the sections, the reaction product was developed for 5 minutes using 3,3′-diaminobenzidine (DAB) (Dako, Carpinteria, CA), counterstained with hematoxylin and then dehydrated and mounted in a permanent medium (Consul Mount; Thermo Fisher Scientific Inc. Waltham, MA, USA). As a positive control breast cancer sections were used. The sections were viewed through the Nikon Eclipse 80i (Nikon Instruments Europe BV, Badhoevedorp, the Netherlands).

The intensity of the staining of both the cytoplasm and membrane was evaluated. The percentage of stained cells was also evaluated using the subjective method of the succeeding approximations we previously described (Jozwicki et al. [@CR17]). Staining intensity was evaluated as negative (0) or positive with a grade of 1+ (pale brown), 2+ (brown) or 3+ (dark brown).

Ki67 immunostaining was performed using consecutive sections. After deparaffinization, rehydration and antigen retrieval using PT Link and high pH buffer (Dako, Carpinteria, CA), the endogenous peroxidase activity was quenched with a 3% solution of H2O2. Anti-Ki67 primary monoclonal mouse antibody, clone MIB-1 (Dako), at dilution 1:100 with EnVision™ FLEX Antibody Diluent (Dako, Carpinteria, CA) was then applied for 30 minutes. Next, the subsequent steps of immunostaining were performed as in RCAS1 labeling. Finally, the percentage of Ki67-positive cancer cells was evaluated in both the high and low proliferative areas.

Definitions used methodologically: CI (Cytoplasmatic Immunoreactivity) -- the staining level of cytoplasmatic structures of the cancer cell; MI (Membrane Immunoreactivity) -- the staining level of the cell membrane of the cancer cell; CP (Central Part) -- the older part of the tumor, without signs of dynamic growth; BP (Border Part) -- the younger part of the tumor, with signs of dynamic growth (e.g., the presence of small nests of tumor cells, expressions of stromal reactivity, as inflammatory infiltration and/or types of stromal modeling pattern).

The categorization of the central and border parts of the tumors was carried out by means of morphological assessment. Later, Ki67 immunostaining was performed in order to evaluate the rate of proliferation in given areas. We determined the 40%-cutoff point based on the percentage of Ki67-positive cancer cells (calculated as follows: mean percentage of Ki67-positive cells for central parts +1SD). The proliferation rate in the areas of the tumors initially defined as central parts was significantly a lower when compared to the rate in the areas defined as border parts (p \< 0.0001). In the central parts of the tumors, 22.75% of the cells were Ki67-positive while in the border parts 53.70% were Ki67-positive. The areas showing a higher proliferation rate than the cutoff point were classified as border parts while the areas with a proliferation rate below this point were classified as central parts Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Ki67 immunostaining in ovarian cancer. **a**) The arrow indicates the area with a high proliferation rate of the border part of the tumor with a newly invasive ovarian cancer cell group. The arrow heads indicate areas of the central part of the tumor showing a lower percentage of the Ki67-positive cells. Scale bar 100 μm. **b**) The enlarged area of the central part of the tumor. Scale bar = 50 μm. **c**) The enlarged area of the newly invasive ovarian cancer cell group. Scale bar = 50 μm

Statistical analysis {#Sec5}
--------------------

The distribution of variables in the study groups of women checked with the use of the Shapiro-Wilk test showed that each of the women was different from normal. The statistical significance between the groups was determined by the Kruskal-Wallis test, one-way analysis of variance by ranks. The Mann-Whitney U test was then used as applicable. All statistical analyses were carried out with the Statistica 8.0 software program. A p value \< 0.05 was considered indicative of statistical significance.

Results {#Sec6}
=======

The characteristic of RCAS1 immunoreactivity {#Sec7}
--------------------------------------------

### RCAS1 immunoreactivity within the cancer milieu {#Sec8}

The levels of RCAS1 immunoreactivity within the cancer nest were not uniform; the chief differences that we found were between the levels in the central and border parts of the tumor. Many apoptotic cells were seen in the central part of the tumor, which was characterized by high stromal hyalinization, a small number of fibroblasts, either absence or presence of single macrophages and little or no inflammatory reactivity in the tumor microenvironment. In the border portion of the cancer nest, by contrast, the proliferation was distinct. For this reason, we decided to distinguish two parts of the cancer nest, the central part and the border part and to analyze the RCAS1 immunoreactivity levels independently as CP versus BP. Nevertheless, as the ovarian cancer cells were typified by cytoplasmatic and membrane expression of RCAS1, we analysed the RCAS1 immunoreactivity in the cytoplasm independently of the membrane RCAS1 expression as CI vs MI Fig. [2](#Fig2){ref-type="fig"} Table [2](#Tab2){ref-type="table"}.Fig. 2RCAS1 immunoreactivity within the ovarian cancer nest. Scale bars = 50 μm. **a**) Cytoplasmatic RCAS1 immunoreactivity (CI) within the ovarian cancer cells derived from the central part of the tumor (CP) with predominant minimal staining expression 1+. **b**) Cytoplasmatic RCAS1 immunoreactivity (CI) within the ovarian cancer cells derived from the central part of the tumor (CP) with predominant maximal staining expression 2+. **c**) Membrane RCAS1 immunoreactivity (MI) within the ovarian cancer cells derived from the central part of the tumor (CP) with predominant minimal staining expression 0. **d**) Membrane RCAS1 immunoreactivity (MI) within the ovarian cancer cells derived from the central part of the tumor (CP) with predominant maximal staining expression 1+. **e**) Cytoplasmatic RCAS1 immunoreactivity (CI) within the ovarian cancer cells derived from the border part of the tumor (BP) with predominant minimal staining expression 2+. **f**) Cytoplasmatic RCAS1 immunoreactivity (CI) within the ovarian cancer cells derived from the border part of the tumor (BP) with predominant maximal staining expression 3+. **g**) Membrane RCAS1 immunoreactivity (MI) within the ovarian cancer cells derived from the border part of the tumor (BP) with predominant minimal staining expression 0. **h**) Membrane RCAS1 immunoreactivity (MI) within the ovarian cancer cells derived from the border part of the tumor (BP) with predominant maximal staining expression 2+Table 2RCAS1 immunoreactivity levels (cytoplasmatic and membrane immunoreactivity of RCAS1) within the ovarian cancer milieuImmunostaining Intensity0^1^1^1^2^1^3^1^CP-cytoplasm4 (5.4)42 (56.8)27 (36.5)1 (1.3)CP-membrane58 (78.4)12 (16.2)4 (5.4)0 (0.0)BP-cytoplasm0 (0.0)3 (4.1)41 (55.4)30 (40.5)BP-membrane38 (51.4)12 (16.2)16 (21.6)8 (10.8)^1^ -- Number of samples (percentage of samples)

### RCAS1 immunoreactivity within the ovarian cancer microenvironment {#Sec9}

The level of RCAS1 immunoreactivity was detected within the cells surrounding the cancer nest, namely, macrophages (TAM) and carcinoma-associated fibroblasts (CAF)*.* We observed significant differences in RCAS1 immunoreactivity levels between the cells infiltrating the cancer nest microenvironment and those surrounding the central part of the tumor Fig. [3](#Fig3){ref-type="fig"} Table [3](#Tab3){ref-type="table"}.Fig. 3RCAS1 immunoreactivity within cells infiltrating the ovarian cancer microenvironment. Scale bars = 50 μm. a) Predominant minimal RCAS1 immunoreactivity within CAF in the central part of the tumor (CP) (staining expression 0). b) Predominant maximal RCAS1 immunoreactivity within CAF in the central part of the tumor (CP) (staining expression 1+) c) Predominant minimal RCAS1 immunoreactivity within CAF in the border part of the tumor (BP) (staining expression 1+). d) Predominant maximal RCAS1 immunoreactivity within CAF in the border part of the tumor (BP) (staining expression 2+). e) Predominant minimal RCAS1 immunoreactivity within the macrophages infiltrating the central part of the tumor (CP) (staining expression 0). Two regions of the tissue section are showed. f) Predominant maximal RCAS1 immunoreactivity within the macrophages infiltrating the central part of the tumor (CP) (staining expression 2+). ). Two regions of the tissue section are shown. g) Predominant minimal RCAS1 immunoreactivity within the macrophages in the border part of the tumor (BP) (staining expression 2+). h) Predominant maximal RCAS1 immunoreactivity within the macrophages in the border part of the tumor (BP) (staining expression 3+)Table 3RCAS1 immunoreactivity levels in macrophages and fibroblasts (CAF) within the ovarian cancer microenvironmentImmunostaining Intensity0^1^1^1^2^1^3^1^CP-macrophages^2^39 (52.7)10 (13.5)15 (20.3)6 (8.1)CP-CAF20 (27.0)44 (59.5)10 (13.5)0 (0.0)BP-macrophages^3^10 (13.5)4 (5.4)31 (41.9)27 (36.5)BP-CAF3 (4.1)43 (58.1)24 (32.4)4 (5.4)^1^ -- Number of samples (percentage of samples), ^2^ -- In 4 of the samples there were no macrophages, ^3^ -- In 2 of the samples there were no macrophages

RCAS1 immunoreactivity relative to the clinicopathological features {#Sec10}
===================================================================

We found statistically significant differences in RCAS1 immunoreactivity within both macrophages and CAFs and these differences corresponded to either the presence or absence of lymph node metastases. The RCAS1 immunoreactivity levels were higher in the patients with lymph node metastases (FIGO IIIc) in comparison to those patients without lymph node metastases. The cases in which the differences were statistically significant are presented in Fig. [4](#Fig4){ref-type="fig"}.Fig. 4Comparison of RCAS1 immunoreactivity according to the presence of lymph node metastases: A) without or B) with. **a**) Cytoplasmatic RCAS1 immunoreactivity (CI) within the ovarian cancer cells derived from the central part of the tumor (CP) **b**) Membrane RCAS1 immunoreactivity (MI) within the ovarian cancer cells derived from the central part of the tumor (CP) **c**) Membrane RCAS1 immunoreactivity (MI) within the ovarian cancer cells derived from the border part of the tumor (BP) **d**) RCAS1 immunoreactivity within CAFs derived from the central part of the tumor (CP) **e**) RCAS1 immunoreactivity within macrophages derived from the central part of the tumor (CP)

In the BP of the tumor, both the RCAS1 cytoplasmatic immunoreactivity (CI) and RCAS1 immunoreactivity within CAF and macrophages were higher in the cases with lymph node metastases than in those without lymph node metatases; the differences, however, were not statistically significant.

The differences in RCAS1 relative to the grade of the tumor were observed only in the cytoplasm (CI) of ovarian cancer cells derived from the central part of the tumor.

RCAS1 immunoreactivity relative to the applied therapy {#Sec11}
======================================================

We have observed significantly lower RCAS1 cytoplasmatic immunoreactivity levels in the border parts of the tumors derived from patients for whom first-line chemotherapy was sufficient in comparison to the levels in those patients who required second-line chemotherapy (p = 001). In addition, we observed statistically significantly higher levels of RCAS1 immunoreactivity within the macrophages in the central part of the tumor derived from those patients on whom neoadjuvant chemotherapy was applied before cytoreductive surgery in comparison to the levels found in the macrophages within the tissue samples derived from patients on whom primary cytoreductive surgery was performed (p = 0.01). Similarly, the level of membrane RCAS1 immunoreactvity in the central part of the tumor was significantly higher in those patients who underwent neoadjuvant chemotherapy but these differences were not statistically significant (p = 0.08). Furthermore, there was a significantly higher infiltration of RCAS1 positive macrophages in the central part of the tumor in patients with malignant ascites in comparison to those patients without ascites but this difference was, again, not statistically significant (p = 0.09)

Discussion {#Sec12}
==========

The suppressive profile of the tumor microenvironment differs according to the tumor zone and may be related to the development of metastases since a tumor depends on its microenvironment for its growth. Most likely, the proliferating zones of the tumor have different microenvironments and this can be detected by the RCAS1 immunoreactivity level. The cancer cells from proliferating zones may develop metastases because the surrounding cells create the conditions favorable for tumor progression. The tumor grows within the stroma that is prepared to support this growth. The presence of an increased number of fibroblasts demonstrating different types of histological dynamic mutual arrangements with cancer nests (modeling pattern: Fig. [1C](#Fig1){ref-type="fig"}) along with an increased number of inflammatory cells (e.g., macrophages) may indicate that a proper environment for the growth of the tumor has been established. This is especially true if there is also an increased expression of RCAS1 (Fig. [1](#Fig1){ref-type="fig"}). The stronger expression of RCAS1 on macrophages is likely connected with the presence of the M2 macrophage phenotype (Basta et al. [@CR4]). While M1 macrophages are associated with an anti-cancer response and are able to increase the activation of T lymphocytes and NK cell trough secretion of such cytokines as interleukin-12 or TNF alfa, M2 macrophages seem to cooperate with cancer cells and constitute the main part of the suppressive profile that surrounds the tumor. M2 macrophages produce mainly IL-10 and their increased infiltration is linked with a poorer prognosis for the case in various types of carcinomas (Nagamatsu and Schust [@CR21]). RCAS1-positive macrophages were observed in various types of cancer, including salivary gland carcinoma or brain tumors (Adamek et al. [@CR1]; Dutsch-Wicherek [@CR5]; Dutsch-Wicherek et al. [@CR7]). The infiltration of these cells corresponds to cancer progression (Dutsch-Wicherek et al. [@CR7]). RCAS1-positive macrophages were not detected in the ovarian cancer microenvironment, although RCAS1 was observed in both the cytoplasm and membrane of ovarian cancer cells within the cancer nest (Akahira et al. [@CR2]; Sonoda et al. [@CR29]; [@CR30]). Moreover, RCAS1 expression in the cancer nest was higher in those patients who had advanced ovarian cancer (Akahira et al. [@CR2]). Similarly, Sonoda et al. have observed that patients with advanced ovarian cancer have higher RCAS1 blood serum concentration levels (Sonoda et al. [@CR29]). The different structures of these different microenvironments may be reflected in their different RCAS1 expression profiles and changes in RCAS1 immunoreactivity may indicate different functional potential. Certainly, RCAS1 may support the development of the suppressive profile of the tumor microenvironment. Recently, Sonoda et al*.* found that the level of RCAS1 correlates inversely with the number of Vimentin positive cells within the microenvironment of the ovarian cancer (Sonoda et al. [@CR30]). These cells participate in connective tissue remodeling, which is in turn directly linked with overall survival rates. Thus patients with higher RCAS1 expression (and so lower Vimentin positive cells) have statistically significantly lower survival rates (Sonoda et al. [@CR30]). In our study we did not assess survival rates relative to the level of RCAS1 immunoreactivity but we did observe higher RCAS1 immunoreactivity levels in patients who had lymph node metastases. These data may suggest a relationship between RCAS1 expression and poor prognosis. Clearly it cannot be ignored that as RCAS1 increases, an inhibition of infiltrating cytotoxic T lymphocytes and NK cells comes into play that allows cancer cells to evade immune surveillance and the tumor to grow. In our study we compared various clinical parameters associated with the outcome of applied therapy, such as the number of required chemotherapy regiments, the need for neo-adjuvant chemotherapy application and the primary cytoreductive surgery application. Additionally, we observed alterations in RCAS1 immunoreactivity levels in cases where there was a response to applied therapy in comparison to those typified by resistance to the applied therapy. In cases where resistance to therapy was observed, it was generally linked with a poor prognosis. Therefore, alteration in the microenvironment profile, as measured by the level of RCAS1 immunoreactivity, may help to predict resistance to therapy and such resistance indicates a higher biological potential for the tumor to disseminate.

Conclusion {#Sec13}
==========

RCAS1 immunoreactivity is diffuse and not homogeneous and so the levels of RCAS1 immunoreactivity detected in the various parts of the tumor differ. RCAS1 staining may provide information about the intensity of the immune-suppressive microenvironment profile of ovarian cancer; the intensity of this suppressive profile may in turn be related to the clinical outcome of the disease treatment.
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